Should I buy or sell Taysha Gene Therapies stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSHA shares. View TSHA analyst ratings or view top-rated stocks .

What is Taysha Gene Therapies' stock price target for 2024?

11 brokerages have issued 1-year target prices for Taysha Gene Therapies' stock. Their TSHA share price targets range from $3.00 to $10.00. On average, they expect the company's stock price to reach $5.89 in the next twelve months. This suggests a possible upside of 229.0% from the stock's current price. View analysts price targets for TSHA or view top-rated stocks among Wall Street analysts .

How have TSHA shares performed in 2023?

Taysha Gene Therapies' stock was trading at $2.26 at the start of the year. Since then, TSHA stock has decreased by 20.8% and is now trading at $1.79. View the best growth stocks for 2023 here .

Are investors shorting Taysha Gene Therapies?

Taysha Gene Therapies saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 13,950,000 shares, an increase of 42.9% from the October 31st total of 9,760,000 shares. Based on an average trading volume of 2,490,000 shares, the days-to-cover ratio is presently 5.6 days. View Taysha Gene Therapies' Short Interest .

When is Taysha Gene Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our TSHA earnings forecast .

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.02) by $0.33. Taysha Gene Therapies had a negative net margin of 1,498.57% and a negative trailing twelve-month return on equity of 1,790.06%. During the same period last year, the company posted ($1.28) earnings per share.

When did Taysha Gene Therapies IPO?

(TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager.

Who are Taysha Gene Therapies' major shareholders?

Taysha Gene Therapies' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (13.12%), RA Capital Management L.P. (9.88%), RTW Investments LP (9.04%), Acuta Capital Partners LLC (2.05%), Kynam Capital Management LP (1.76%) and Polar Capital Holdings Plc (1.35%). Insiders that own company stock include John A Stalfort III, Kamran Alam , Paul B Manning , Phillip B Donenberg , RA Session II , Sean P Nolan , Sukumar Nagendran and Suyash Prasad. View institutional ownership trends .

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Taysha Gene Therapies Stock Price, News & Analysis (NASDAQ:TSHA)

$1.79

-0.01 (-0.56%)

(As of 11/28/2023 ET)

Compare

Today's Range: $1.74
▼
$1.85
50-Day Range: $1.33
▼
$3.16
52-Week Range: $0.50
▼
$3.89

Volume: 2.90 million shs
Average Volume: 2.02 million shs
Market Capitalization: $334.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.89

Taysha Gene Therapies MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.73 Rating Score
Upside/Downside: 229.0% Upside
$5.89 Price Target
Short Interest: Bearish
7.46% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.37
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$163,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.69) to ($0.45) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

723rd out of 949 stocks

Biological Products, Except Diagnostic Industry

123rd out of 160 stocks

3.4

Analyst's Opinion

Consensus Rating
Taysha Gene Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.89, Taysha Gene Therapies has a forecasted upside of 229.0% from its current price of $1.79.
Amount of Analyst Coverage
Taysha Gene Therapies has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.46% of the outstanding shares of Taysha Gene Therapies have been sold short.
Short Interest Ratio / Days to Cover
Taysha Gene Therapies has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in Taysha Gene Therapies has recently increased by 42.93%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Taysha Gene Therapies does not currently pay a dividend.
Dividend Growth
Taysha Gene Therapies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TSHA.

2.4

News and Social Media Coverage

News Sentiment
Taysha Gene Therapies has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Taysha Gene Therapies this week, compared to 1 article on an average week.
Search Interest
8 people have searched for TSHA on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $163,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.25% of the stock of Taysha Gene Therapies is held by insiders.
Percentage Held by Institutions
Only 25.91% of the stock of Taysha Gene Therapies is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Taysha Gene Therapies are expected to grow in the coming year, from ($0.69) to ($0.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Taysha Gene Therapies is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Taysha Gene Therapies is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Taysha Gene Therapies has a P/B Ratio of 89.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Taysha Gene Therapies Stock (NASDAQ:TSHA)

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

TSHA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TSHA Stock News Headlines

November 26, 2023 | morningstar.com

Taysha Gene Therapies Inc Ordinary Shares

November 25, 2023 | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $5.89 Consensus Target Price from Brokerages

November 29, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

November 24, 2023 | finance.yahoo.com

Insider Buying: Taysha Gene Therapies Board Observer Bought US$163k Of Shares

November 21, 2023 | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Paul B. Manning Purchases 100,000 Shares

November 20, 2023 | americanbankingnews.com

Cantor Fitzgerald Analysts Reduce Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

November 20, 2023 | americanbankingnews.com

Chardan Capital Analysts Boost Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

November 19, 2023 | finance.yahoo.com

Party Time: Brokers Just Made Major Increases To Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Earnings Forecasts

November 29, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

November 17, 2023 | finance.yahoo.com

Analysts Are Upgrading Taysha Gene Therapies, Inc. (NASDAQ:TSHA) After Its Latest Results

November 17, 2023 | markets.businessinsider.com

Buy Rating for Taysha Gene Therapies: Promising Efficacy of TSHA-102 in Rett Syndrome Treatment and Strong Financial Position

November 15, 2023 | markets.businessinsider.com

Buy Rating for Taysha Gene Therapies Amid Significant Patient Improvement and Promising Therapeutic Product Efficacy

November 14, 2023 | finance.yahoo.com

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

November 14, 2023 | finance.yahoo.com

Taysha Gene Therapies Inc (TSHA) Reports Q3 2023 Financial Results and Clinical Progress

November 13, 2023 | benzinga.com

A Preview Of Taysha Gene Therapies's Earnings

November 7, 2023 | finance.yahoo.com

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

October 24, 2023 | finance.yahoo.com

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

October 10, 2023 | finance.yahoo.com

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

September 26, 2023 | finance.yahoo.com

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

September 21, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Taysha Gene Therapies (TSHA), Harmony Biosciences Holdings (HRMY)

September 20, 2023 | msn.com

Dallas-based biotech firm Taysha drops gene therapy following FDA meeting

September 19, 2023 | marketwatch.com

Stocks to Watch: Cambridge Bancorp, Taysha Gene Therapies, Sonder Holdings

September 19, 2023 | markets.businessinsider.com

Taysha Discontinues Development Of TSHA-120 In Giant Axonal Neuropathy

September 19, 2023 | msn.com

2 Healthcare Stocks That More Than Tripled Recently. Can They Keep Climbing?

September 5, 2023 | finance.yahoo.com

Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?

August 31, 2023 | msn.com

Taysha Gene Therapies (TSHA) Price Target Increased by 11.47% to 5.84

August 16, 2023 | msn.com

Dallas biotech snags $150 million lifeline for gene therapy pipeline

See More Headlines

Receive TSHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TSHA
CUSIP: N/A
CIK: 1806310
Web: www.tayshagtx.com
Phone: 214-612-0000
Fax: N/A
Employees: 65
Year Founded: 2020

Price Target and Rating

Average Stock Price Target: $5.89
High Stock Price Target: $10.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +229.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.73
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-166,010,000.00
Net Margins: -1,498.57%
Pretax Margin: -1,494.08%
Return on Equity: -1,790.06%
Return on Assets: -90.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.95
Quick Ratio: 0.95

Sales & Book Value

Annual Sales: $2.50 million
Price / Sales: 133.86
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.02 per share
Price / Book: 89.50

Miscellaneous

Outstanding Shares: 186,960,000
Free Float: 182,753,000
Market Cap: $334.66 million
Optionable: Not Optionable
Beta: 0.13

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Sean P. Nolan (Age 55)
CEO & Chairman
Comp: $674k
Dr. Sukumar Nagendran M.D. (Age 56)
President, Head of Research & Development and Director
Comp: $619.1k
Mr. Kamran Alam CPA (Age 45)
M.B.A., CFO & Corporate Secretary
Comp: $703.61k
Hayleigh Collins
Director & Head of Corporate Communications
Ms. Tracy M. Porter SPHR
Chief People Officer
Mr. Frederick Porter Ph.D.
Chief of Staff & Technical Operations Officer
Ms. Emily McGinnis M.P.H.
Chief Patient Advocacy & External Affairs Officer
Mr. Sean McAuliffe
Chief Business Officer
Dr. Steven Gray Ph.D.
Chief Scientific Advisor of UT Southwestern Gene Therapy Program
Berge Minassian M.D.
Chief Medical Advisor of UT Southwestern Gene Therapy Program

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TSHA Stock Analysis - Frequently Asked Questions

Should I buy or sell Taysha Gene Therapies stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSHA shares.
View TSHA analyst ratings or view top-rated stocks.
What is Taysha Gene Therapies' stock price target for 2024?: 11 brokerages have issued 1-year target prices for Taysha Gene Therapies' stock. Their TSHA share price targets range from $3.00 to $10.00. On average, they expect the company's stock price to reach $5.89 in the next twelve months. This suggests a possible upside of 229.0% from the stock's current price.
View analysts price targets for TSHA or view top-rated stocks among Wall Street analysts.
How have TSHA shares performed in 2023?: Taysha Gene Therapies' stock was trading at $2.26 at the start of the year. Since then, TSHA stock has decreased by 20.8% and is now trading at $1.79.
View the best growth stocks for 2023 here.
Are investors shorting Taysha Gene Therapies?: Taysha Gene Therapies saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 13,950,000 shares, an increase of 42.9% from the October 31st total of 9,760,000 shares. Based on an average trading volume of 2,490,000 shares, the days-to-cover ratio is presently 5.6 days.
View Taysha Gene Therapies' Short Interest.
When is Taysha Gene Therapies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our TSHA earnings forecast.

How were Taysha Gene Therapies' earnings last quarter?: Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.02) by $0.33. Taysha Gene Therapies had a negative net margin of 1,498.57% and a negative trailing twelve-month return on equity of 1,790.06%. During the same period last year, the company posted ($1.28) earnings per share.
When did Taysha Gene Therapies IPO?: (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager.
Who are Taysha Gene Therapies' major shareholders?: Taysha Gene Therapies' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (13.12%), RA Capital Management L.P. (9.88%), RTW Investments LP (9.04%), Acuta Capital Partners LLC (2.05%), Kynam Capital Management LP (1.76%) and Polar Capital Holdings Plc (1.35%). Insiders that own company stock include John A Stalfort III, Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II, Sean P Nolan, Sukumar Nagendran and Suyash Prasad.
View institutional ownership trends.
How do I buy shares of Taysha Gene Therapies?: Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TSHA) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial